July 28, 2016 5:33pm
… The open, morning, mid-day and closing trades were negative
I warned in posts … last night and this am!
My pre-open indications – 6 hits (ADRO, BLCM, KOOL, JUNO, KITE and SGMO) and 0 miss:
I answer one question; in which company should investors put, keep and commit their money!
Do you care what happened today, you should … because it has implications to Friday's sector activity? Where has today’s market gone – subscribe and find out.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. stocks closed mostly higher Thursday while the NASDAQ outperformed, holding a touch lower in midday trade. The S&P 500 traded mildly lower.
The NASDAQ closed UP +15.17 or +0.30% to 5,154.98 and the DOW closed DOWN -15.82 or -0.09% to 18,456.35.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 18/21 and 4 flats;
- The mid-day stayed negative with an A/DL of 16/26 and 1 flat;
- The closing bell was negative with A/DL of 15/22 and 6 flats;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened negative, stayed negative at the mid-day with the sector closing negative.
- What did I say in last evening’s post … did you want to keep the chips on the table?
“BUY signals are beginning to conflict <in my eyes> … has a top been recognized? It might just be the time to fold and take your money than to risk going long over a summer weekend.”
- And as I stated this am, too many investors buy when the sector is at a peak and sell during a downturn … there are risks going long over a summer weekend.
It all came TRUE!
Call me cantankerous, contrarian or even a curmudgeon but at last I get it right …
Review my fear gauge or the CBOE Volatility Index (VIX):
- Thursday traded near 12.6;
- Wednesday traded below 13;
- Tuesday traded above 13;
- Monday traded above 13;
- Friday traded near 12.17;
- Last, Thursday traded near 12.73;
Today’s Bottom Line:
Having experienced the overbought, we head back to the oversold – the merry-go-round music continues to play-on!
My pre-open indications – 6 hit and 0 miss:
- Aduro Biotech (ADRO) closed DOWN -$0.01 – hit;
- Bellicum Pharma (BLCM) closed DOWN -$0.63 – hit;
- Cesca Therapeutics closed DOWN -$0.33 – hit;
- Juno Therapeutics (JUNO) closed DOWN -$0.46 – hit;
- Kite Pharma (KITE) closed UP +$0.29 – hit;
- Sangamo (SGMO) closed DOWN -$0.18 – hit;
Largest decliners:
- Cesca Therapeutics (KOOL) -7.50% after Wednesday’s -11.47% after Tuesday’s+44.06% after Monday’s +9.87%;
- Stem Cells (STEM) -5.17% after Wednesday’s -5.58%
- ImmunoCellular (NYSEMKT: IMUC) -3.89%;
- Bellicum Pharma (BLCM) -3.85% after Wednesday’s +10.23%;
- Intrexon (XON) -3.36%
Advancers:
- Caladrius Biosciences (CLBS) +953.56% after a 1 for 10 reverse split; Wednesday’s -10.33% post Tuesday’s +7.41%;
- Verastem (VSTM) +13.85% or +$0.18;
- Adverum (ADVM) +8.71% or +$0.29;
- Neuralstem (CUR) +7.16% or +$0.0163;
Flat:
- AxoGen (AXGN) at $6.72;
- Biostage (BSTG) at $1.10;
- ReNeuron (RENE.L) at $3.00;
- Vericel (VCEL) at $2.15;
- Fibrocell (FCSC) at $1.09;
- Regenxbio (RGNX) at $8.27
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
